UBS Group’s Zealand Pharma A/S American Depositary Shares ZEAL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-351
| Closed | -$4K | – | 11646 |
|
|
2022
Q2 | $4K | Sell |
351
-546
| -61% | -$7K | ﹤0.01% | 9253 |
|
|
2022
Q1 | $13K | Sell |
897
-60
| -6% | -$1.01K | ﹤0.01% | 8129 |
|
|
2021
Q4 | $21K | Buy |
957
+813
| +565% | +$20.7K | ﹤0.01% | 7821 |
|
|
2021
Q3 | $4K | Buy |
144
+114
| +380% | +$3.43K | ﹤0.01% | 8761 |
|
|
2021
Q2 | $1K | Sell |
30
-1,173
| -98% | -$36.6K | ﹤0.01% | 9292 |
|
|
2021
Q1 | $38K | Buy |
1,203
+1,173
| +3,910% | +$39.5K | ﹤0.01% | 6815 |
|
|
2020
Q4 | $1K | Hold |
30
| – | – | ﹤0.01% | 8298 |
|
|
2020
Q3 | $1K | Hold |
30
| – | – | ﹤0.01% | 7884 |
|
|
2020
Q2 | $1K | Sell |
30
-1,123
| -97% | -$39.9K | ﹤0.01% | 7848 |
|
|
2020
Q1 | $40K | Buy |
+1,153
| New | +$40.2K | ﹤0.01% | 6008 |
|
|
2019
Q4 | – | Sell |
-756
| Closed | -$19K | – | 8551 |
|
|
2019
Q3 | $19K | Buy |
756
+111
| +17% | +$2.51K | ﹤0.01% | 6780 |
|
|
2019
Q2 | $14K | Sell |
645
-1,762
| -73% | -$35.6K | ﹤0.01% | 6869 |
|
|
2019
Q1 | $41K | Sell |
2,407
-87
| -3% | -$1.3K | ﹤0.01% | 5709 |
|
|
2018
Q4 | $29K | Buy |
2,494
+1,211
| +94% | +$15.9K | ﹤0.01% | 6516 |
|
|
2018
Q3 | $21K | Sell |
1,283
-327
| -20% | -$4.94K | ﹤0.01% | 6777 |
|
|
2018
Q2 | $20K | Buy |
+1,610
| New | +$24.5K | ﹤0.01% | 6704 |
|
|
2017
Q4 | – | Sell |
-277
| Closed | -$5K | – | 8204 |
|
|
2017
Q3 | $5K | Buy |
+277
| New | +$5.22K | ﹤0.01% | 7252 |
|
Other funds holding ZEAL
UBS Group's ZEAL Position: Q3 2022 in Review
UBS Group sold out of Zealand Pharma A/S American Depositary Shares (ZEAL) in Q3 2022, closing a stake of 351 shares — an estimated $4K sold.
UBS Group first reported a position in ZEAL in Q3 2017 and held it in 17 quarters. The position peaked at $41K in Q1 2019. 1 fund tracked by Wall St. Rank holds ZEAL as of Q3 2022.
- UBS Group reported no remaining Zealand Pharma A/S American Depositary Shares position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 351 Zealand Pharma A/S American Depositary Shares shares in Q3 2022, an estimated $4K.
- UBS Group first reported a position in Zealand Pharma A/S American Depositary Shares in Q3 2017 and held it in 17 quarters.
- UBS Group's Zealand Pharma A/S American Depositary Shares position peaked at $41K in Q1 2019.
- 1 fund tracked by Wall St. Rank held Zealand Pharma A/S American Depositary Shares as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.